176 related articles for article (PubMed ID: 36625987)
1. The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients.
Fan W; Liu H; Shen Y; Hong K
Cardiovasc Drugs Ther; 2024 Jun; 38(3):517-525. PubMed ID: 36625987
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Medication Associated with QTc Prolongation Used Among Critically Ill Patients.
Al-Azayzih A; Al-Qerem W; Al-Azzam S; Muflih S; Al-Husein BA; Kharaba Z; Kanaan RJ; Rahhal D
Vasc Health Risk Manag; 2024; 20():27-37. PubMed ID: 38318252
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study.
Pickham D; Helfenbein E; Shinn JA; Chan G; Funk M; Weinacker A; Liu JN; Drew BJ
Crit Care Med; 2012 Feb; 40(2):394-9. PubMed ID: 22001585
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients.
Freeman BD; Dixon DJ; Coopersmith CM; Zehnbauer BA; Buchman TG
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):971-81. PubMed ID: 18693297
[TBL] [Abstract][Full Text] [Related]
7. QT prolongation and safety in the Indian population.
Dabhi J; Mehta A
Curr Drug Saf; 2007 Sep; 2(3):200-3. PubMed ID: 18690968
[TBL] [Abstract][Full Text] [Related]
8. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
Khan Q; Ismail M; Haider I; Ali Z
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients.
Tisdale JE; Jaynes HA; Kingery JR; Overholser BR; Mourad NA; Trujillo TN; Kovacs RJ
Circ Cardiovasc Qual Outcomes; 2014 May; 7(3):381-90. PubMed ID: 24803473
[TBL] [Abstract][Full Text] [Related]
11. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.
Uvelin A; Pejaković J; Mijatović V
J Anesth; 2017 Jun; 31(3):413-423. PubMed ID: 28229241
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
13. [Drug induced QT prolongation].
Altmann D; Eggmann U; Ammann P
Wien Klin Wochenschr; 2008; 120(5-6):128-35. PubMed ID: 18365152
[TBL] [Abstract][Full Text] [Related]
14. The Incidence of QT Prolongation and Torsades des Pointes in Patients Receiving Droperidol in an Urban Emergency Department.
Cole JB; Lee SC; Martel ML; Smith SW; Biros MH; Miner JR
West J Emerg Med; 2020 Jul; 21(4):728-736. PubMed ID: 32726229
[TBL] [Abstract][Full Text] [Related]
15. Proton Pump Inhibitor Use Before ICU Admission Is Not Associated With Mortality of Critically Ill Patients.
Shi L; Zhang D
J Clin Pharmacol; 2020 Jul; 60(7):860-866. PubMed ID: 32043627
[TBL] [Abstract][Full Text] [Related]
16. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
Das B; Rawat VS; Ramasubbu SK; Kumar B
Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
[TBL] [Abstract][Full Text] [Related]
17. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
18. Predictive Validity of a QT
Su K; McGloin R; Gellatly RM
Pharmacotherapy; 2020 Jun; 40(6):492-499. PubMed ID: 32259316
[TBL] [Abstract][Full Text] [Related]
19. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
[TBL] [Abstract][Full Text] [Related]
20. The CredibleMeds
Then MI; Andrikyan W; Maas R; Fromm MF
Br J Clin Pharmacol; 2022 Jan; 88(1):226-236. PubMed ID: 34156728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
